Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?

Literature DB >> 29221236

Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?

Paul Zarogoulidis¹, Vasilis Papadopoulos², Elena Maragouli², George Papatsibas², Haidong Huang³.

Abstract

Entities: Disease Gene Species

Year: 2017 PMID： 29221236 PMCID： PMC5708388 DOI： 10.21037/jtd.2017.08.24

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

19 in total

1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors: Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal: Lancet Date: 2015-12-19 Impact factor: 79.321

2. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors: Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal: Cancer Discov Date: 2013-09-27 Impact factor: 39.397

3. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.

Authors: R Hui; E B Garon; J W Goldman; N B Leighl; M D Hellmann; A Patnaik; L Gandhi; J P Eder; M-J Ahn; L Horn; E Felip; E Carcereny; R Rangwala; G M Lubiniecki; J Zhang; K Emancipator; C Roach; N A Rizvi
Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976

4. Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

Authors: Tri Le; Joseph Sailors; Dwight H Oliver; Melissa Mayer; Sharon Hoskin; David E Gerber
Journal: Lung Cancer Date: 2017-01-11 Impact factor: 5.705

5. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245

6. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

7. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

Authors: Jordi Remon; Jessica Menis; Baktiar Hasan; Aleksandra Peric; Eleonora De Maio; Silvia Novello; Martin Reck; Thierry Berghmans; Bartosz Wasag; Benjamin Besse; Rafal Dziadziuszko
Journal: Clin Lung Cancer Date: 2017-03-01 Impact factor: 4.785

8. Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.

Authors: Paul Zarogoulidis; Aggeliki Rapti; Chrysanthi Sardeli; Panagiotis Chinelis; Anastasia Athanasiadou; Katerina Paraskevaidou; Anastasios Kallianos; Lemonia Veletza; Georgia Trakada; Wolfgang Hohenforst-Schmidt; Haidong Huang
Journal: Respir Med Case Rep Date: 2017-05-30